Fresenius Kabi
Recent News About Fresenius Kabi View More
-
Shareholder suit alleges Akorn, Fresenius merger benefits leadership, doesn't do enough for investors
A group of investors wants a court to keep German pharmaceutical firm Fresenius from buying Illinois drug maker Akorn, saying shareholders won’t get enough from the deal, which is valued at more than $4 billion.